Top BRD4 inhibition by ABBV-744 in cancer research studies Secrets
In Phase C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment right up until illness progression or maybe the participants are not able to tolerate the study drugs.88 These preclinical studies provide paradigms for potential clinical trials in AML,